共同實驗室(六)

組長   劉家源 醫師、 林俊昌 醫師

進駐研究醫師：
兒科部 李宏昌
心臟內科 洪崇烈
胃腸肝膽科 張經緯、賴建翰
中醫部 李以荍、徐培倩

研究人員

江謝正雄 博士、謝姎紋 博士
廖淑芳、李俐慧、張鳳婷、鄭美蓮

運用NGS技術, 使用CLC等生物資訊軟體進行腸道菌相分析。

使用益生菌(Probiotics)及各種改良式微菌叢植入(Fecal Microbiota Transplantation)，進行相關疾病的療效及可能機轉研究。

運用大腸癌植入小鼠，接受5-FU/FOLFOX後產生化學治療引發腹瀉之動物模型，接受各種治療，進行發炎、增生及細胞凋亡等途徑之機制研究。

建立飲食誘發肥胖脂肪肝模型，產生具有類似代謝症候群的小鼠動物模式，以評估代謝及脂肪肝相關疾病（如心血管疾病）之致病機轉與可能途徑。

肝臟腫瘤之病人雖經根治性之治療(開刀切除、射頻燒灼、肝臟移植)，仍有不少病人面臨腫瘤復發或轉移之困擾，近年雖有標靶治療藥物及免疫治療，但臨床治療成績仍不夠理想，如能找出肝臟腫瘤之復發與轉移機轉，將對廣大的肝臟腫瘤族群提供很大的幫助。目前已建立肝臟腫瘤病人檢體組織陣列，將繼續以免疫組織染色方法染肝臟腫瘤病人檢體組織陣列，研究可能造成肝癌復發及轉移之因子。

蔡司Zeiss Axio Imager.A2正立光學/微分干涉相差/螢光顯微鏡
細胞抹片機 (cytospin)
腸道菌相檢測：illumina MiSeq NGS儀器設備、CLC Genomics Workbench 等分析軟體

Lee CY, Liu CY, Wu YJ, Lin CC. Analysis of Intensive Care and ACGME Core Competencies between PGY2 and R1 Residents of Internal Medicine. International Journal of Gerontology 2023; 17(2): 124-129. (SCIE, GERIATRICS & GERONTOLOGY) (IF. 0.3, Ranking= 73/74 =98.6%)

Chang SH, Chu PH, Tsai CT, Kuo JY, Tsai JP, Hung TC, Hou CJ, Lai YH, Liu CY, Huang WM, Yun CH, Yeh HI, Hung CL. Both epicardial and peri-aortic adipose tissue blunt heart rate recovery beyond body fat mass. Frontiers in Cardiovascular Medicine 2022; 9:939515. (SCIE, CARDIAC & CARDIOVASCULAR SYSTEMS) (IF. 2.8, Ranking= 79/222 =35.6%)

Hsu K, Liu YY, Tseng WC, Huang KT, Liu CY, Chen LY, Lee HL, Lin HJ, Tseng KW, Yeh HI. Comodulation of NO-Dependent Vasodilation by Erythroid Band 3 and Hemoglobin: A GP.Mur Athlete Study. Frontiers in Cardiovascular Medicine 2021; 8:740100. (SCIE, CARDIAC & CARDIOVASCULAR SYSTEMS) (IF. 2.8, Ranking= 79/222 =35.6%)

Hung CL, Sung KT, Chang SC, Liu YY, Kuo JY, Huang WH, Su CH, Liu CC, Tsai SY, Liu CY, Lee AS, Pan SH, Wang SW, Hou CJ, Hung TC, Yeh HI. Variant Aldehyde Dehydrogenase 2 (ALDH2*2) as a Risk Factor for Mechanical LA Substrate Formation and Atrial Fibrillation with Modest Alcohol Consumption in Ethnic Asians. Biomolecules 2021; 11(11):1559. (SCIE, BIOCHEMISTRY & MOLECULAR BIOLOGY) (IF. 4.8, Ranking= 67/313 =21.4%)

Yeung CY, Chiang Chiau JS, Cheng ML, Chan WT, Jiang CB, Chang SW, Liu CY, Chang CW, Lee HC. Effects of Vitamin D-Deficient Diet on Intestinal Epithelial Integrity and Zonulin Expression in a C57BL/6 Mouse Model. Frontiers in Medicine (Lausanne) 2021; 8:649818. (SCIE, MEDICINE, GENERAL & INTERNAL) (IF. 3.1, Ranking= 57/329 =17.3%)

Liu JH, Hsieh CH, Liu CY, Chang CW, Chen YJ, Tsai TH. Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. Journal of Ethnopharmacology 2021; 271:113912. (SCIE, INTEGRATIVE & COMPLEMENTARY MEDICINE) (IF. 4.8, Ranking= 4/43 =9.3%)

Chang CW, Lee HC, Li LH, Chiang Chiau JS, Wang TE, Chuang WH, Chen MJ, Wang HY, Shih SC, Liu CY, Tsai TH, Chen YJ. Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin -Induced Toxicity in Colorectal Cancer. International Journal of Molecular Sciences 2020; 21(2) (Co-corresponding author) (SCIE, BIOCHEMISTRY & MOLECULAR BIOLOGY) (IF. 4.9, Ranking= 66/313 =21.1%)

Lin JC, Liu TP, Chen YB, Yang PM. PF-429242 exhibits anticancer activity in hepatocellular carcinoma cells via FOXO1-dependent autophagic cell death and IGFBP1-dependent anti-survival signaling. American Journal of Cancer Research 2023; 13(9):4125-4144. (SCIE, ONCOLOGY) (IF. 3.6, Ranking= 106/322 =32.9%)

Lin JC, Liu TP, Chen YB, Huang TS, Chen TY, Yang PM. Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase. Toxicology and Applied Pharmacology 2023; 471:116568. (SCIE, PHARMACOLOGY & PHARMACY) (IF. 3.3, Ranking= 119/354 =33.6%)

Lin JC, Liu TP, Andriani V, Athoillah M, Wang CY, Yang PM. Bioinformatics analysis identifies precision treatment with paclitaxel for hepatocellular carcinoma patients harboring mutant TP53 or wild-type CTNNB1 gene. Journal of Personalized Medicine 2021; 11(11):1199. (SCIE, MEDICINE, GENERAL & INTERNAL) (IF. 3.0, Ranking= 59/329 =17.9%) 

Lin JC, Yang PM, Liu TP. PERK/ATF4-dependent ZFAS1 upregulation is associated with sorafenib resistance in hepatocellular carcinoma cells. International Journal of Molecular Sciences 2021; 22(11):5848. (SCIE, BIOCHEMISTRY & MOLECULAR BIOLOGY) (IF. 4.9, Ranking= 66/313 =21.1%)

Lin JC, Liu CL, Chang YC, Cheng SP, Huang WC, Lin CH, Wu CY, Chen MJ. Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib. Investigational New Drugs 2021; 39(6):1493-1506. (SCIE, PHARMACOLOGY & PHARMACY) (IF. 3.0, Ranking= 136/354 =38.4%)

Lin JC, Liu TP, Yang PM. CDKN2A-inactivated pancreatic ductal adenocarcinoma exhibits therapeutic sensitivity to paclitaxel: A bioinformatics study. Journal of Clinical Medicine 2020; 9(12):4019. (SCIE, MEDICINE, GENERAL & INTERNAL) (IF. 3.0, Ranking= 59/329 =17.9%)